CN113730640A - 一种可原位交联的海绵敷料及其制备方法 - Google Patents
一种可原位交联的海绵敷料及其制备方法 Download PDFInfo
- Publication number
- CN113730640A CN113730640A CN202111094501.7A CN202111094501A CN113730640A CN 113730640 A CN113730640 A CN 113730640A CN 202111094501 A CN202111094501 A CN 202111094501A CN 113730640 A CN113730640 A CN 113730640A
- Authority
- CN
- China
- Prior art keywords
- sponge dressing
- situ
- sponge
- dressing
- double
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011065 in-situ storage Methods 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 21
- 239000002243 precursor Substances 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 19
- 239000005017 polysaccharide Substances 0.000 claims abstract description 19
- 239000002195 soluble material Substances 0.000 claims abstract description 18
- 239000000835 fiber Substances 0.000 claims abstract description 17
- 108010010803 Gelatin Proteins 0.000 claims abstract description 16
- 239000008273 gelatin Substances 0.000 claims abstract description 16
- 229920000159 gelatin Polymers 0.000 claims abstract description 16
- 235000019322 gelatine Nutrition 0.000 claims abstract description 16
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 13
- 150000004804 polysaccharides Chemical class 0.000 claims description 18
- 235000010443 alginic acid Nutrition 0.000 claims description 8
- 229920000615 alginic acid Polymers 0.000 claims description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
- 239000000783 alginic acid Substances 0.000 claims description 6
- 229960001126 alginic acid Drugs 0.000 claims description 6
- 150000004781 alginic acids Chemical class 0.000 claims description 6
- 239000000648 calcium alginate Substances 0.000 claims description 6
- 235000010410 calcium alginate Nutrition 0.000 claims description 6
- 229960002681 calcium alginate Drugs 0.000 claims description 6
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 6
- 229920002674 hyaluronan Polymers 0.000 claims description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 5
- 230000002787 reinforcement Effects 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- -1 acryl Chemical group 0.000 claims description 4
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 claims description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- 229960002086 dextran Drugs 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- KLGDRWGOXDJNPH-UHFFFAOYSA-N P(=O)(O)(O)O.C1(=CC=CC=C1)C=1C(=C(C(=O)[Li])C(=CC1C)C)C Chemical compound P(=O)(O)(O)O.C1(=CC=CC=C1)C=1C(=C(C(=O)[Li])C(=CC1C)C)C KLGDRWGOXDJNPH-UHFFFAOYSA-N 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 125000005641 methacryl group Chemical group 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 16
- 208000027418 Wounds and injury Diseases 0.000 abstract description 16
- 238000004132 cross linking Methods 0.000 abstract description 9
- 239000007788 liquid Substances 0.000 abstract description 5
- 230000005284 excitation Effects 0.000 abstract description 2
- 239000000017 hydrogel Substances 0.000 abstract description 2
- 150000004676 glycans Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 17
- 238000010521 absorption reaction Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 6
- 238000001723 curing Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000004745 nonwoven fabric Substances 0.000 description 6
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- 230000002439 hemostatic effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000000016 photochemical curing Methods 0.000 description 4
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011056 performance test Methods 0.000 description 3
- 239000012779 reinforcing material Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000009777 vacuum freeze-drying Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IGAAQDGISNXKQL-UHFFFAOYSA-L P(=O)(OC(C1=C(C(=C(C=C1C)C)C1=CC=CC=C1)C)=O)([O-])[O-].[Li+].[Li+] Chemical compound P(=O)(OC(C1=C(C(=C(C=C1C)C)C1=CC=CC=C1)C)=O)([O-])[O-].[Li+].[Li+] IGAAQDGISNXKQL-UHFFFAOYSA-L 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 238000009864 tensile test Methods 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- LSWCMUBJZBXTDM-UHFFFAOYSA-M P(=O)(OC1=CC=CC=C1)(OC(C1=C(C=C(C=C1C)C)C)=O)[O-].[Li+] Chemical compound P(=O)(OC1=CC=CC=C1)(OC(C1=C(C=C(C=C1C)C)C)=O)[O-].[Li+] LSWCMUBJZBXTDM-UHFFFAOYSA-M 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010048629 Wound secretion Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000011858 nanopowder Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003211 polymerization photoinitiator Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2/00—Processes of polymerisation
- C08F2/46—Polymerisation initiated by wave energy or particle radiation
- C08F2/48—Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F299/00—Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明提供一种可原位交联的海绵敷料及其制备方法。其中,海绵敷料包括可光固化水溶性材料和光引发剂,可光固化水溶性材料至少包括双键改性明胶和双键改性天然聚多糖。本发明提出的海绵敷料接触湿润伤口后会迅速吸水溶胀为水凝胶前驱体,随后通过激发光源辐照实现原位交联固化。该海绵敷料可快速吸收湿润伤口液体并与组织高度贴合,原位交联固化过程使其紧密粘附于组织表面,纤维增强材料可提高敷料力学强度,有效保护伤口。本发明的制备方法,该制备方法过程简单,易操作。
Description
技术领域
本发明属于生物材料及医用技术领域,具体涉及一种可原位交联的海绵敷料及其制备方法。
背景技术
自湿性伤口愈合理论提出以来,近几十年出现了大量基于湿态的伤口敷料,如水胶体敷料、藻酸盐敷料等。湿性伤口愈合理论是指在伤口局部湿润不形成结痂的前提下,护理时创造接近生理状态的湿性愈合环境,就有利于肉芽的生长,便于皮肤细胞的分裂,从而促使伤口的完整愈合。
现有基于湿性伤口愈合理论的上市产品主要包括海绵敷料、藻酸盐敷料、水胶体敷料等。这些产品与湿性伤口的作用力很小,通常需要外侧覆盖额外的固定粘接层以防止敷料脱落。
为了实现敷料与组织的良好粘接,专利文献CN109908086A公开了一种基于甲基丙烯酰化明胶(GelMA)的原位固化止血粉剂敷料。该止血粉是通过将GelMA与光引发剂混合溶液进行超临界二氧化碳造粒得到。粉体为纳米级别颗粒,通过喷雾方式将止血粉施加到伤口上。GelMA纳米颗粒在伤口处的溶解吸水形成凝胶,使得伤口快速止血,随后通过光交联使得GelMA凝胶快速固化,实现隔水和伤口保护,同时由于原位固化的方式,该止血材料可与组织有一定粘接力。但该方案仅简单采用GelMA纳米粉末,通过原位交联作为止血敷料,原位固化后粉末间不能有效结合,材料力学强度较差,难以应用于创面类修复。此外,GelMA材料的吸水性不佳,不利于迅速吸收渗血渗液。
发明内容
为解决现有敷料的不足,本发明提出一种可原位交联的海绵敷料,其由亲水性光固化材料、纤维增强材料及光引发剂组成。海绵敷料接触湿润伤口后会迅速吸水溶胀为水凝胶前驱体,随后通过激发光源辐照实现原位交联固化。该海绵敷料可快速吸收湿润伤口液体并与组织高度贴合,原位交联固化过程使其紧密粘附于组织表面,纤维增强材料可提高敷料力学强度,有效保护伤口。
本发明还提供上述可原位交联的海绵敷料的制备方法,该制备方法过程简单,易操作。
为实现上述目的,本发明提供的技术方案如下:
一种可原位交联的海绵敷料,包括可光固化水溶性材料和光引发剂,所述可光固化水溶性材料至少包括双键改性明胶和双键改性天然聚多糖。
上述技术方案中,可光固化水溶性材料中,双键改性明胶可以与皮肤组织间形成很好的氢键,具有较好的粘连性;双键改性天然聚多糖具有较好的吸水性;二者搭配使用,使海绵敷料兼具吸水性和粘连性,后通过光固化交联成型,能够有效提高该海绵敷料与皮肤组织之间的粘附强度。
作为优选,所述双键改性明胶为丙烯酰基或甲基丙烯酰基改性明胶。
作为进一步优选,所述双键改性明胶为甲基丙烯酰化明胶(GelMA)。
作为优选,所述双键改性天然聚多糖为丙烯酰基或甲基丙烯酰基改性天然聚多糖。作为进一步优选,所述双键改性天然聚多糖为甲基丙烯酰基改性天然聚多糖。
作为优选,所述天然聚多糖为透明质酸、海藻酸、葡聚糖、葡聚糖、硫酸软骨素、羧甲基壳聚糖、羟丙甲纤维素中的一种或多种。
作为进一步优选,所述天然聚多糖为透明质酸或海藻酸。
作为进一步优选,所述双键改性天然聚多糖为甲基丙烯酰化透明质酸(HAMA)或甲基丙烯酰化海藻酸(AlgMA)。
作为优选,可光固化水溶性材料中,所述双键改性明胶与双键改性天然聚多糖的质量比为(1~5):2。进一步优选为(1~3):2。
作为优选,所述可光固化水溶性材料与光引发剂的质量比为1:(0.01~0.5)。进一步优选为1:(0.02~0.3)。
作为优选,所述可光固化水溶性材料与光引发剂的质量比为(1~5):(0.05~0.5)。
作为优选,所述光引发剂为水溶性自由基聚合光引发剂。
作为优选,所述光引发剂为I2959、VA086、苯基(2,4,6-三甲基苯甲酰基)磷酸锂盐(LAP)中的一种或多种。进一步优选为苯基(2,4,6-三甲基苯甲酰基)磷酸锂盐(LAP)。
为了提高可原位交联的海绵敷料的力学强度,作为优选,本发明的可原位交联的海绵敷料还包括纤维增强材料。
所述纤维增强材料的纤维排布可为无序或有序。进一步优选为所述纤维增强材料的纤维有序排布。
作为进一步优选,所述可光固化水溶性材料与纤维增强材料的质量比为1:(0.1~5)。更进一步优选为1:(0.15~2.5)。
作为进一步优选,所述可光固化水溶性材料与纤维增强材料的质量比为(1~5):(0.5~5)。
作为进一步优选,所述纤维增强材料为通过熔喷、静电纺丝、溶液纺丝、针刺等工艺制备的多孔膜或片状材料。
作为进一步优选,所述纤维增强材料为海藻酸钙、壳聚糖、羧甲基纤维素、聚己内酯、聚乙交酯-丙交酯、聚乳酸纤维中的一种或多种。进一步优选为海藻酸钙。
作为进一步优选,所述纤维增强材料为海藻酸钙无纺布。
本发明提供一种可原位交联的海绵敷料的制备方法,其过程包括前驱体溶液的配制、模具浇注、冷冻干燥。
其中,冷冻干燥的作用是除去海绵敷料中的水分,同时可以保持海绵敷料较好的孔隙结构。
一种上述任一项所述的可原位交联的海绵敷料的制备方法,包括以下步骤:
(1)将可光固化水溶性材料、光引发剂溶于水中,制备前驱体溶液;
(2)将上述前驱体溶液浇注入模具(冻干机样品盘)中,冷冻干燥,得所述可原位交联的海绵敷料。
作为优选,所述可光固化水溶性材料与水的质量比为(1~5):100。
作为优选,步骤(1)中,将可光固化水溶性材料、光引发剂以此加入水中,避光加热搅拌至充分溶解,得到前驱体溶液。
作为进一步优选,加热温度为40~60℃。进一步优选为50℃。
作为优选,步骤(2)中,冷冻干燥包括先在冷冻干燥机中-15~-80℃预冷冻1~24h,后真空冻干。
作为进一步优选,所述预冷冻时,冷冻温度为-15~-30℃,冷冻时间为15~25h。
作为优选,当所述可原位交联的海绵敷料包括纤维增强材料时,在前驱体溶液浇注入模具之前,将所述纤维增强材料平铺于所述模具的底部,随后倒入前驱体溶液,待纤维增强材料被前驱体溶液充分浸润后再进行后续的冷冻干燥。
与现有技术相比,本发明的有益效果为:
本发明的制备方法将双键改性的变性胶原(明胶)与天然聚多糖(透明质酸、海藻酸)组合作为伤口敷料,成分上更接近天然细胞外基质的组成。亲水性天然聚多糖成分的引入提高了敷料材料的液体吸收能力。本发明的可原位交联的海绵敷料以非交联冻干凝胶前驱体聚合物形式提供,可迅速吸收大量伤口渗血渗液,紧密贴合于组织表面。采用原位光固化方式使吸水的敷料交联成型,提高其与组织间的粘附强度。为了提升敷料力学性能,引入纤维增强组分,使敷料固化后能更好抵抗外部应力,防止敷料破裂。本发明原位交联海绵敷料在口腔及皮肤等伤口止血及护理领域有广阔应用前景。
附图说明
图1为实施例1中制得的海绵敷料的横截面SEM图;
图2为实施例1中制得的海绵敷料的表面SEM图;
图3为图2的放大图。
具体实施方式
为了使得本发明更容易理解,本发明结合下面附图和实施例对本发明做进一步说明:
实施例1:
海绵敷料制备过程:
1)将1g GelMA、1g AlgMA及0.1g LAP依次投入100g去离子水中,50℃避光搅拌至所有物料充分溶解,制备前驱体溶液。
2)取海藻酸钙无纺布纤维增强材料0.5g平铺于冻干机样品盘(模具)中,将上述前驱体溶液趁热倒入盘中,使前驱体溶液完全浸润无纺布。
3)将载有前驱体溶液和无纺布的样品盘放入冷冻干燥机,预冷冻温度为-20℃,预冷冻时间18h,随后进行真空冻干,即得可原位交联的海绵敷料。
本实施例制得的海绵敷料的横截面和外表面SEM图分别见图1~3。
实施例2~4:
制备过程与实施例1相同,不同之处在于具体工艺参数及各配料添加量的不同,实施例2~4的具体工艺参数及各配料添加量见表1,并分别得到实施例2~4的海绵敷料。
表1实施例2-4对应的工艺参数及各配料的添加量
对比例1:
海绵敷料制备过程:
制备过程与实施例1相同,不同之处在于:第1)步中AlgMA添加质量为0,得到对比例1的海绵敷料。
实施例5:
敷料制备过程:
1)将1g GelMA、1g HAMA及0.1g LAP依次投入100g去离子水中,50℃避光搅拌至所有物料充分溶解,制备前驱体溶液。
2)取海藻酸钙无纺布纤维增强材料0.5g平铺于冻干机样品盘(模具)中,将上述前驱体溶液趁热倒入盘中,使前驱体溶液完全浸润无纺布。
3)将样品盘放入冷冻干燥机,预冷冻温度为-20℃,预冷冻时间18h,随后进行真空冻干,得可原位交联的海绵敷料。
实施例6~8:
制备过程与实施例5相同,不同之处在于具体工艺参数及各配料添加量的不同,实施例6~8的具体工艺参数及各配料添加量见表2,并分别得到实施例6~8的海绵敷料。
表2实施例6-8对应的工艺参数及各配料的添加量
分别对实施例1~8、对比例1中制得的海绵敷料进行如下性能测试:
1.吸水时间测试
准备50mL PBS缓冲液,温度37℃,取0.1g海绵敷料样品投入PBS缓冲液中,同时用秒表记录样品完全沉入液面所用的时间。
2.吸水率测试
在吸水时间测试计时结束时,立即捞出吸水溶胀的样品,进行称重。吸水率按照(吸水样品质量-干态样品质量)/干态样品质量计算,结果以百分比记录。
3.拉伸测试测试
将敷料制成长5cm,宽2cm的尺寸,置于玻璃平面,用移液枪向样品均匀滴加PBS溶液至样品不能再吸收液体为止。用光强50mW/cm2波长405nm光源距离样品2cm辐照固化30s。
将样品加载到万能试验机上,进行拉伸测试,杨氏模量根据样品尺寸及厚度计算,同时记录断裂伸长率。
经过上述测试后,实施例1~8、对比例1中制得的海绵敷料的性能测试结果如表3所示。
表3实施例1~8及对照例1中制得的海绵敷料的性能测试数据
由表3中的测试结果可以看出,与对比例1中仅含GelMA的海绵敷料相比,实施例1~8的海绵敷料的吸水时间上有明显提升,均可控制在15s以内,且吸水率均高于50%的提升。通过光固化交联后的材料的杨氏模量和断裂伸长率也有明显提升。说明,采用GelMA与AlgMA或HAMA的组合物的形式作为制备海绵敷料的原料,能有有效改善海绵敷料的吸水性能,以及光固化交联后材料的机械性能。
Claims (10)
1.一种可原位交联的海绵敷料,其特征在于,包括可光固化水溶性材料和光引发剂,所述可光固化水溶性材料至少包括双键改性明胶和双键改性天然聚多糖。
2.根据权利要求1所述的可原位交联的海绵敷料,其特征在于,所述双键改性明胶为丙烯酰基或甲基丙烯酰基改性明胶;
所述双键改性天然聚多糖为丙烯酰基或甲基丙烯酰基改性天然聚多糖。
3.根据权利要求1所述的可原位交联的海绵敷料,其特征在于,所述天然聚多糖为透明质酸、海藻酸、葡聚糖、葡聚糖、硫酸软骨素、羧甲基壳聚糖、羟丙甲纤维素中的一种或多种。
4.根据权利要求2或3所述的可原位交联的海绵敷料,其特征在于,所述双键改性明胶为甲基丙烯酰化明胶;
所述双键改性天然聚多糖为甲基丙烯酰化透明质酸或甲基丙烯酰化海藻酸。
5.根据权利要求1所述的可原位交联的海绵敷料,其特征在于,可光固化水溶性材料中,所述双键改性明胶与双键改性天然聚多糖的质量比为(1~5):2。
6.根据权利要求1所述的可原位交联的海绵敷料,其特征在于,所述可光固化水溶性材料与光引发剂的质量比为1:(0.01~0.5)。
7.根据权利要求1所述的可原位交联的海绵敷料,其特征在于,所述光引发剂为I2959、VA086、苯基(2,4,6-三甲基苯甲酰基)磷酸锂盐中的一种或多种。
8.根据权利要求1~7任一项所述的可原位交联的海绵敷料,其特征在于,还包括纤维增强材料。
9.根据权利要求8所述的可原位交联的海绵敷料,其特征在于,所述纤维增强材料为海藻酸钙、壳聚糖、羧甲基纤维素、聚己内酯、聚乙交酯-丙交酯、聚乳酸纤维中的一种或多种。
10.一种如权利要求1~9中任一项所述的可原位交联的海绵敷料的制备方法,其特征在于,包括以下步骤:
(1)将可光固化水溶性材料、光引发剂溶于水中,制备前驱体溶液;
(2)将上述前驱体溶液浇注入模具中,冷冻干燥,得所述可原位交联的海绵敷料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111094501.7A CN113730640A (zh) | 2021-09-17 | 2021-09-17 | 一种可原位交联的海绵敷料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111094501.7A CN113730640A (zh) | 2021-09-17 | 2021-09-17 | 一种可原位交联的海绵敷料及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113730640A true CN113730640A (zh) | 2021-12-03 |
Family
ID=78739708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111094501.7A Pending CN113730640A (zh) | 2021-09-17 | 2021-09-17 | 一种可原位交联的海绵敷料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113730640A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023169028A1 (zh) * | 2022-03-09 | 2023-09-14 | 南方科技大学 | 一种止血海绵及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103113700A (zh) * | 2013-01-18 | 2013-05-22 | 盐城工学院 | 互穿网络结构水凝胶创面敷料及其制备方法 |
US20140224266A1 (en) * | 2013-02-12 | 2014-08-14 | Hratch A. Kardachian | Method for modifying a base water matrix prior to adding a super absorbant acrylic based copolymer such as in order to form a flavored gelatinous composition suited for use with smoking devices |
CN107469127A (zh) * | 2017-08-04 | 2017-12-15 | 北京化工大学常州先进材料研究院 | 天然多糖衍生物/天然高分子复合纤维医用伤口敷料的制备方法 |
CN109568642A (zh) * | 2018-11-29 | 2019-04-05 | 天津大学 | 一种具有快速止血和长效抗菌功效的多聚糖基止血海绵 |
CN111228565A (zh) * | 2020-01-21 | 2020-06-05 | 海南卓瑞生物医药有限公司 | 一种载plga微球的透明质酸-明胶复合水凝胶及其制备方法 |
CN113244437A (zh) * | 2021-06-15 | 2021-08-13 | 福州大学 | 一种仿生多功能复合海绵敷料的制备方法与应用 |
-
2021
- 2021-09-17 CN CN202111094501.7A patent/CN113730640A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103113700A (zh) * | 2013-01-18 | 2013-05-22 | 盐城工学院 | 互穿网络结构水凝胶创面敷料及其制备方法 |
US20140224266A1 (en) * | 2013-02-12 | 2014-08-14 | Hratch A. Kardachian | Method for modifying a base water matrix prior to adding a super absorbant acrylic based copolymer such as in order to form a flavored gelatinous composition suited for use with smoking devices |
CN107469127A (zh) * | 2017-08-04 | 2017-12-15 | 北京化工大学常州先进材料研究院 | 天然多糖衍生物/天然高分子复合纤维医用伤口敷料的制备方法 |
CN109568642A (zh) * | 2018-11-29 | 2019-04-05 | 天津大学 | 一种具有快速止血和长效抗菌功效的多聚糖基止血海绵 |
CN111228565A (zh) * | 2020-01-21 | 2020-06-05 | 海南卓瑞生物医药有限公司 | 一种载plga微球的透明质酸-明胶复合水凝胶及其制备方法 |
CN113244437A (zh) * | 2021-06-15 | 2021-08-13 | 福州大学 | 一种仿生多功能复合海绵敷料的制备方法与应用 |
Non-Patent Citations (1)
Title |
---|
顾其胜: "《壳聚糖基海洋生物医用材料》", 31 December 2020, 上海科学技术出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023169028A1 (zh) * | 2022-03-09 | 2023-09-14 | 南方科技大学 | 一种止血海绵及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110240712B (zh) | 一种组织粘合用的高拉伸、高粘性、自愈合双网络水凝胶及其制备方法和应用 | |
CN102258801B (zh) | 一种海藻酸钙海绵医用敷料及其制备方法 | |
Yang et al. | Preparation and characterisation of a novel silk fibroin/hyaluronic acid/sodium alginate scaffold for skin repair | |
CN106822183B (zh) | 一种光敏富血小板血浆凝胶及其制备方法和用途 | |
CN105833331B (zh) | 一种可降解生物创伤敷料的制备方法及所得产品 | |
CN109106977B (zh) | 一种用于糖尿病创面修复的自愈合可注射水凝胶敷料及其制备方法与应用 | |
CN108853570B (zh) | 一种止血海绵及其制备方法 | |
CN109453420B (zh) | 止血组合物及其制备方法和用途 | |
CN111870732B (zh) | 一种可诱导组织再生修复的止血颗粒及其制备方法和应用 | |
CN102973984A (zh) | 一种复合材料多孔支架的制备方法与应用 | |
CN102580138A (zh) | 一种用于止血的多糖复合膜及其制备方法 | |
CN104001211B (zh) | 一种骨组织工程复合多孔支架材料及其制备方法 | |
CN113730640A (zh) | 一种可原位交联的海绵敷料及其制备方法 | |
CN115154658B (zh) | 一种吸水自粘硬脊膜补片的制备方法和应用 | |
CN113082286A (zh) | 一种基于3d打印技术的三层仿生皮肤支架及其制备方法 | |
Liu et al. | A multi-functional double cross-linked chitosan hydrogel with tunable mechanical and antibacterial properties for skin wound dressing | |
CN112023109A (zh) | 一种可粘附自修复止血膜及其制备方法 | |
Yang et al. | Preparation of methacrylated hyaluronate/methacrylated collagen sponges with rapid shape recovery and orderly channel for fast blood absorption as hemostatic dressing | |
Liao et al. | A good adhesion and antibacterial double-network composite hydrogel from PVA, sodium alginate and tannic acid by chemical and physical cross-linking for wound dressings | |
CN114316162A (zh) | 光交联可注射纳米纤维-水凝胶复合物及其制备方法与应用 | |
CN113144275A (zh) | 一种水凝胶粘合剂及其制备方法和应用 | |
CN117018269A (zh) | 一种仿贻贝多功能丝素蛋白基粘合剂及其制备方法与应用 | |
CN112007210A (zh) | 一种光引发聚乙二醇基水凝胶敷料及其制备方法 | |
CN115671372A (zh) | 可制备双交联纤维蛋白粘合剂的原料组合物及方法 | |
Song et al. | Preparation of Multi‐Functional Quaternary Ammonium Chitosan/Surfactin Hydrogel and its Application in Wound Management |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211203 |
|
RJ01 | Rejection of invention patent application after publication |